Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,499.50GBp
2:38pm IST
Change (% chg)

-2.50 (-0.05%)
Prev Close
5,502.00
Open
5,523.00
Day's High
5,538.00
Day's Low
5,498.00
Volume
234,862
Avg. Vol
1,938,390
52-wk High
5,538.00
52-wk Low
4,260.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 30.93 32.76
EPS (TTM): 2.34 -- --
ROI: 7.86 15.07 14.61
ROE: 28.47 16.60 16.34

Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

06 Jul 2018

Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

LONDON AstraZeneca suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

06 Jul 2018

FOCUS-Hitting cancer early: AstraZeneca's bid to outmanoeuvre rivals

* Drugmaker gets its mojo back a year after cancer study flop

06 Jul 2018

AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

27 Jun 2018

UPDATE 1-AstraZeneca, Merck eye $1 bln boost from cancer drug success

* Puts drug ahead of competition in PARP medicine race (Adds analyst reaction, sales forecasts)

27 Jun 2018

AstraZeneca, Merck eye wider cancer drug use after study success

LONDON, June 27 AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

27 Jun 2018

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

12 Jun 2018

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

June 12 Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

12 Jun 2018

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca's first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

30 May 2018

AstraZeneca cancer drug hits second goal by extending survival

LONDON AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

25 May 2018

Earnings vs. Estimates